Purchase this article with an account.
W. F. Mieler, II, InSight CNV Registry Oversight Committee; An Interim Analyis of the InSight CNV Registry: A Collaborative Initiative to Advance AMD Treatment. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4574.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The clinical management of age-related macular degeneration (AMD) is undergoing a revolution with the emergence of new drugs and treatment strategies. The need to urgently address these changing trends has inspired the creation of the InSight CNV Registry which is disease-based evaluating long-term outcomes with all AMD treatment options.
The objectives of the InSight CNV Registry are to document real-world experience with AMD treatments including evolving trends and combination approaches.Sixty three centers across the U.S. are participating including both community practices as well as academic centers. Patients were deemed eligible after a diagnosis of choroidal neovascularization was made. Data can be entered prospectively or retrospectively to January 1, 2005 and enrollment formally ends on December 31, 2006. The Registry will remain active until December 31, 2008.The data collected include patient demographics, medical and ocular history, lesion type, size and location. Outcome measures include distance visual acuity, OCT, fluorescein and ICG angiography when available. Also collected is information on the initial treatment, re-treatment or change in treatment, along with the reasons for drug choices and changes in treatment regimen.
An interim analysis of the Registry data for approximately 650 patients with CNV secondary to exudative AMD will be presented. For the first 500 patients at baseline the mean±SD age was 77.9 ± 12.1years, 62.7% were female and 89.0% were Caucasian. The median Snellen visual acuity was 20/125 and lesion types were as follows: 40% predominantly classic, 18% minimally classic, 30% occult with no classic while 12% were unknown. Mean central retinal thickness by OCT was 285.4µm.Six months and one year follow-up data will be presented.
It is hoped that data from the Registry will provide further insight into the evolving treatment trends and, ultimately, shed some light on optimal treatment strategies for patients with exudative AMD.
This PDF is available to Subscribers Only